A recent study reported on an anti-CD19/anti-CD3 single-chain bispecific antibody (bscCD19xCD3) exhibiting high activity against human B lymphoma cell lines (LΓΆffler et al., Blood 2000;95:2098-103). In the present study, we have explored in detail the in vitro efficacy, T-cell donor variability, bin
β¦ LIBER β¦
CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help
β Scribed by Glennie, Martin J.; French, Ruth R.; Chan, H.T. Claude; Tutt, Alison L.
- Book ID
- 109829845
- Publisher
- Nature Publishing Group
- Year
- 1999
- Tongue
- English
- Weight
- 122 KB
- Volume
- 5
- Category
- Article
- ISSN
- 1078-8956
- DOI
- 10.1038/8426
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Extremely potent, rapid and costimulatio
β
Torsten Dreier; Grit Lorenczewski; Christian Brandl; Patrick Hoffmann; Uwe Syrin
π
Article
π
2002
π
John Wiley and Sons
π
French
β 199 KB
A bispecific single-chain antibody that
β
Rammensee, H-G; Jung, G; Otz, T; GroΓe-Hovest, L; Hofmann, M
π
Article
π
2008
π
Nature Publishing Group
π
English
β 284 KB
Peptide-antibody conjugates for tumour t
β
Zhiwei Yu; Frank Healy; Danila Valmori; Patricia Escobar; Giampietro Corradin; J
π
Article
π
1994
π
John Wiley and Sons
π
French
β 729 KB
Anti-idiotype antibody therapy of B-cell lymphomas, despite numerous promising experimental and clinical studies, has so far met with limited success. Tailor-made monoclonal antiidiotype antibodies have been injected into a large series of lymphoma patients, with a few impressive complete tumour rem
Interferon alpha in combination with GM-
β
Xiao Chen; Sybille Regn; Silke Raffegerst; Hans-Jochem Kolb; Marie Roskrow
π
Article
π
2008
π
John Wiley and Sons
π
English
β 807 KB